METHODS
Forty-nine (35 males, 14 females; median age 55; range 2273 years) resectable gastric cancer patients treated with gastrectomy and adjuvant concurrent chemoradiotherapy were enrolled in this study. All patients received weekly 250 mg/ m2 5-FU chemotherapy and radiotherapy concomittantly after gastrectomy. Then patients received 4 cycles i.v bolus FUFA chemotherapy sequentialy as consolidation treatment 2-4 week after chemoradiotherapy. Immunohistochemistry staining was performed on paraffin embedded tissue. NF-κB monoclonal antibodies were used for the staining.
RESULTS
The progression free surv ival and overall surv ival dif er e nce were anal ised between NF-κB pos it ive and neg at ive groups. For NF-kB a specimen was judged posit ive if more than 10% of the total cancer cells in a single field of view showed a response.
CONCLUSION
In patients who NF-κB was stained more than 10%, the overall survival was worse and there was statistically significant difference between groups. But in two groups, no statistically significant difference due to disease free survival.
Keywords: Chemoradiotherapy; gastric cancer/patoloji; immunohistochemistry; NF-kappa B; prognostic factor; survival rate
